Advantage of SBRT over Surgery for early-stage NSCLC, study by Jochem Kaas
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at UCLA, shared an article by Jochem Kaas on X:
“A new Dutch study demonstrates a clear advantage of SBRT over Surgery for early-stage NSCLC. “
Authors: Jochem Kaas, et al.
Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023